Elraglusib Combo Demonstrates OS Benefit in Metastatic Pancreatic Cancer

Adding elraglusib seen to improve survival in pancreatic cancer trial

Adding the experimental therapy elraglusib to standard chemotherapy led to statistically significant improvements in survival for people with metastatic pancreatic ductal adenocarcinoma (PDAC), a form of advanced pancreatic cancer, in a Phase 2 clinical trial, new data show. These top-line findings were announced by elraglusib’s developer Actuate Therapeutics in a company press release outlining the trial’s positive results. Actuate said that it…

Eraglusib Combo Improves Survival in Metastatic Pancreatic Cancer

Eraglusib with gemcitabine and nab-paclitaxel achieved statistical significance in the first-line treatment of metastatic pancreatic ductal adenocarcinoma.

Elraglusib Combo Demonstrates OS Benefit in Metastatic Pancreatic Cancer

Phase 2 Actuate-1801 part 3B trial results evaluating elraglusib with GnP in metastatic PDAC will be presented at the 2025 ASCO Annual Meeting.